Cibus (CBUS) Projected to Post Quarterly Earnings on Thursday

by · The Cerbat Gem

Cibus (NASDAQ:CBUS – Get Free Report) is projected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $1.3910 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Cibus (NASDAQ:CBUS – Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.08. Cibus had a negative return on equity of 83.67% and a negative net margin of 5,681.55%.The business had revenue of $0.93 million for the quarter, compared to the consensus estimate of $1.15 million. On average, analysts expect Cibus to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cibus Price Performance

NASDAQ:CBUS opened at $1.59 on Thursday. Cibus has a 1 year low of $1.20 and a 1 year high of $6.10. The stock’s 50 day simple moving average is $1.42 and its two-hundred day simple moving average is $1.71. The company has a market cap of $86.24 million, a price-to-earnings ratio of -0.15 and a beta of 1.72.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cibus in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cibus currently has an average rating of “Hold” and an average price target of $21.25.

Check Out Our Latest Report on CBUS

Hedge Funds Weigh In On Cibus

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in shares of Cibus in the 2nd quarter worth approximately $207,000. Raymond James Financial Inc. boosted its holdings in shares of Cibus by 31.0% in the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock worth $74,000 after purchasing an additional 12,722 shares during the period. AQR Capital Management LLC purchased a new position in shares of Cibus in the 1st quarter worth approximately $73,000. Bank of America Corp DE boosted its holdings in shares of Cibus by 113.4% in the 4th quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock worth $99,000 after purchasing an additional 18,885 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Cibus in the 2nd quarter worth approximately $39,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

About Cibus

(Get Free Report)

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.

Featured Articles